Zydus Lifesciences - Guided for 2-3 High Value Launches in US over FY27/28
The stock price has corrected by ~25% over last 3 months on account of concerns of high product concentration risk, incremental competition in...
78 Views
Zydus Lifesciences: High Base to Keep EPS Muted, Specialty Growth Key. Maintain ADD
Zydus Life has corrected over 25% from its 52-week high in the last 2-3 months, due to (1) competition in gAsacol HD (Teva, launched in Sep ’24)
170 Views
Zydus Lifesciences Ltd - Specialty Portfolio Growth to Drive Margins
Sharekhan's research report onZydus Lifesciences We reiterate a Buy on Zydus as domestic sales for February 2024 grew by 11.2% (IPM grew by 9%) and...
396 Views
Pharma and Healthcare (Q2FY25E Results Preview): Steady Q2, Revlimid to Normalise
The India Pharma & Healthcare sector is expected to maintain its growth momentum in Q2FY25E. We project sales/EBITDA growth of 11%/15% YoY for our...
201 Views
Pharma and Healthcare (Q1FY25E Results Preview): Start the Year on a Strong Nod
The India Pharma & Healthcare sector is expected to maintain the growth momentum in Q1FY25E. We expect our coverage universe to see 11%/13% YoY...
222 Views